ABSTRACT

Objective To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation.

Design Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes.

Setting We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010–2016) and reimbursed in Italy.

Main outcome(s) and measure(s) Information on clinical outcomes—in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)—was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients $β$, their levels of significance $p$ and the coefficients of determination $R^2$ were estimated adjusting by tumour type.

Results Overall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price ($R^2=0.067$, n=16 drugs for 17 indications). When the clinical outcomes were expressed as improvements in the median PFS or ORR, 25 drugs (29 indications) were available for the analysis, and again, there was no correlation with prices ($R^2=0.004$ and 0.006, respectively).

Conclusions and relevance Our results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.

BACKGROUND

High costs of cancer drugs and resulting financial toxicity to cancer patients are now a well-recognised problem in cancer policy throughout the world. Various solutions are being proposed to address this problem, of which price negotiations with pharmaceutical companies are proposed as an important strategy, especially in the USA. Because the Medicare is not allowed to negotiate prices with companies, despite being mandated to cover for every US Food and Drug Administration (FDA)-approved drug, various experts have argued that this is the reason for high drug prices in the USA. Indeed, cancer drug prices far exceed the costs of their development, such negotiations might help to lower the prices of cancer drugs as evidenced by lower cost of cancer drugs in other developed countries compared with the USA.

However, little is known about if such negotiations would lead to better correlation between cancer drug prices and the benefits they provide. Studies have shown that drug prices do not correlate with clinical benefits for cancer drugs approved by the FDA, even though such studies have not taken central

Strengths and limitations of this study

- This study is the first attempt to evaluate whether there were better correlations between cancer drug prices and clinical outcomes in a setting where central price negotiations are mandatory for every new medicine.
- This understanding is important for cancer policy decisions.
- In our analysis, the relationship between the clinical outcome and cost of anticancer drugs was ascertained by a simple linear regression model.
- Clinical outcome, which was the dependent variable, was expressed as absolute or per cent differences in outcomes between treatment and control groups.
- The main limitations of our study concern data completeness on clinical outcome and price. We used, as an estimate of benefit, data from pivotal trials retrieved from European Public Assessment Reports.
price negotiations into account. Countries, such as the UK and Italy, negotiate prices and hence, the correlations might be different.

In Italy, drug price negotiation based on cost-effectiveness evaluation has been mandatory since 2001 for all medicines reimbursed by the National Health Service (NHS). We analysed the correlation between the prices of cancer drugs in Italy with their clinical outcomes to test the hypothesis that central price negotiations lead to better alignment of prices and benefits.

METHODS
Identification of the study sample
All new drugs approved by the European Medicines Agency (EMA) via a centralised procedure between January 2010 and June 2016 for the treatment of either solid or haematological cancers were initially identified. Generics, biosimilars, interferons and granulocyte-colony stimulating factors were excluded. Only anticancer drugs with pivotal trials based on overall survival (OS), progression-free survival (PFS) or objective response rate (ORR) and with prices that were officially negotiated in Italy by 31 December 2016 were included in the cohort for analyses.

Data extraction
Information on the clinical outcomes (in terms of median OS, median PFS and ORR) was extracted by two coinvestigators (FB-A and RP) from pivotal trials that compared new treatments with controls as reported in the European Public Assessment Reports (EPARs) (summary table of the main study, Section 2.5.2) publicly available on the EMA website (www.ema.europa.eu). Survival times were expressed in weeks, and the reported OS and PFS were transformed when necessary. Information on therapeutic indication and tumour type were also retrieved.

Drug prices
The cost of a full course or 1-year treatment was estimated by two coinvestigators (NM and IE) on the basis of the negotiated official ex-factory price (in euros) of drug packages, as published in the Official Gazette of the Italian Republic (www.gazzettaufficiale.it) and taking into account the posology as reported in the summary of product characteristics (SPC). To compare prices of drugs with different schedules, in the text, we refer to drug prices as the cost of a full course or a 1-year treatment. A further estimate took into account additional compulsory rebates or extradiscounts that were agreed with pharmaceutical companies; this information is confidential to the public but is released to procurement stations within the Italian NHS (eg, regions, hospitals and local health units).

Statistical analysis
The following variables were extracted and analysed descriptively: year of approval, therapeutic indication, type of treatment and control groups, outcome data, official and confidential costs per treatment (1 year or a full course) and regulatory information (conditional/under exceptional circumstances approval or orphan drug status).

The relationship between the clinical outcomes and cost of anticancer drugs was ascertained by a simple linear regression model. Clinical outcome, which was the dependent variable, was expressed as absolute or percent differences in outcomes between treatment and control groups. Regression coefficients β, their levels of significance p and the coefficients of determination R² were reported for each model.

We also performed several sensitivity analyses to test the robustness of the results. Specifically, we performed multiple linear regression with tumour type as the independent variable to take into account potential differences due to tumour characteristics. Moreover, we also repeated the analysis after excluding negative outcome differences (in two cases, one of the outcomes was inferior in the group receiving the new drug than in the comparison group) and actively controlled trials (considering only placebo-controlled trials). Subgroup analysis by tumour type was also attempted as exploratory analysis when a minimum number of two anticancer drugs within the same tumour type setting were observed. Outlier cases were not excluded from the analyses, but their impact was evaluated and reported when relevant as a separate analysis. All statistical analyses were performed using STATA (StataCorp, V.14.0)

RESULTS
From 2010 to mid-2016, 45 new anticancer drugs for 56 different oncology indications were approved via centralised procedures by the EMA. For 40 new anticancer drugs (47 indications), the basis for the approval was a pivotal trial adopting OS, PFS or ORR as a primary outcome; the price negotiation was completed by December 2016 for only 30 new anticancer drugs (35 indications) which are included in our analysis (table). Seven drugs received orphan drug status by the EMA and two (vandetanib and crizotinib) received conditional approval. Of the 35 oncology indications tested in 35 different pivotal trials which were all controlled clinical trials, the most common indications were melanoma (7 out of 35), followed by haematological cancer (6 out of 35) and non-small-cell lung cancer (4 out of 35). In 15 such trials (43%), placebo was used as the control arm. Of the 35 indications, data on OS, PFS and ORR were
<table>
<thead>
<tr>
<th>Medicine name</th>
<th>Active substance</th>
<th>Clinical setting</th>
<th>Treatment group</th>
<th>Control group</th>
<th>PFS TRT (median in weeks)</th>
<th>PFS CRT (median in weeks)</th>
<th>OS TRT (median in weeks)</th>
<th>OS CRT (median in weeks)</th>
<th>ORR TRT (%)</th>
<th>ORR CRT (%)</th>
<th>Year first authorization</th>
<th>Official negotiated price (€)</th>
<th>Discounted price (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teysuno</td>
<td>Tegafur/gimeracil/oteracil</td>
<td>Advanced gastric cancer in combination with cisplatin</td>
<td>Tegafur/gimeracil/oteracil 25 mg/m²+cisplatin 75 mg/m²</td>
<td>5-fluorouracil 1000 mg/m²/24+ cisplatin 100 mg/m²</td>
<td>25.4</td>
<td>31.6</td>
<td>2011</td>
<td>4942</td>
<td>3479</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jevtana</td>
<td>Cabazitaxel</td>
<td>Hormone-refractory metastatic prostate cancer</td>
<td>Cabazitaxel+prednisone</td>
<td>Mitoxantrone +prednisone</td>
<td>11.2</td>
<td>5.6</td>
<td>2011</td>
<td>52983</td>
<td>38254</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yervoy</td>
<td>Ipilimumab</td>
<td>Advanced (unresectable or metastatic) melanoma</td>
<td>Ipilimumab+Peptide vaccin</td>
<td>Peptide vaccine glycoprotein 100 (gp100)</td>
<td>11.04</td>
<td>11.04</td>
<td>2011</td>
<td>71400</td>
<td>45107</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Votubia</td>
<td>Everolimus</td>
<td>Renal angiomylolipoma associated with tuberous sclerosis complex (TSC)</td>
<td>Everolimus</td>
<td>Placebo</td>
<td>45.48</td>
<td>41.8</td>
<td>2011</td>
<td>66521</td>
<td>41424</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Votubia</td>
<td>Everolimus</td>
<td>Subependymal giant cell astrocytoma associated with TSC</td>
<td>Everolimus</td>
<td>Placebo</td>
<td>34.6</td>
<td>0</td>
<td>2012</td>
<td>53216</td>
<td>33139</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Halaven</td>
<td>Eribulin</td>
<td>Locally advanced or metastatic breast cancer</td>
<td>Eribulin 1.23 mg/m² (equivalent to 1.4 mg/m² eribulin mesylate)</td>
<td>Treatment of physician’s choice</td>
<td>16.14</td>
<td>9.71</td>
<td>2011</td>
<td>32300</td>
<td>28130</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zytiga</td>
<td>Abiraterone acetate</td>
<td>Metastatic castration-resistant prostate cancer</td>
<td>Abiraterone acetate</td>
<td>Placebo</td>
<td>22.4</td>
<td>14.4</td>
<td>2011</td>
<td>46842</td>
<td>33397</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dacogen</td>
<td>Decitabine</td>
<td>Newly diagnosed de novo or secondary acute myeloid leukaemia</td>
<td>Decitabine</td>
<td>Patient’s choice</td>
<td>14.8</td>
<td>8.4</td>
<td>2012</td>
<td>54366</td>
<td>34346</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caprelsa</td>
<td>Vandetanib</td>
<td>Aggressive and symptomatic medullary thyroid cancer unresectable locally advanced or metastatic disease</td>
<td>Vandetanib</td>
<td>Placebo</td>
<td>122</td>
<td>77.2</td>
<td>2012</td>
<td>67405</td>
<td>53533</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zelboraf</td>
<td>Vemurafenib</td>
<td>BRAF-V600-mutation-positive unresectable or metastatic melanoma</td>
<td>Vemurafenib</td>
<td>Dacarbazine</td>
<td>21.28</td>
<td>6.44</td>
<td>2012</td>
<td>119929</td>
<td>108236</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xalkori</td>
<td>Crizotinib</td>
<td>Anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC)</td>
<td>Crizotinib</td>
<td>Pemetrexed or docetaxel</td>
<td>30.8</td>
<td>12</td>
<td>2012</td>
<td>79538</td>
<td>57427</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xalkori</td>
<td>Crizotinib</td>
<td>First-line treatment of adults with ALK positive advanced NSCLC</td>
<td>Crizotinib</td>
<td>Chemotherapy</td>
<td>43.6</td>
<td>28</td>
<td>2012</td>
<td>79538</td>
<td>57427</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inlyta</td>
<td>Axitinib</td>
<td>Advanced renal-cell carcinoma (RCC)</td>
<td>Axitinib</td>
<td>Sorafenib</td>
<td>26.8</td>
<td>18.8</td>
<td>2012</td>
<td>57632</td>
<td>39295</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perjeta</td>
<td>Pertuzumab</td>
<td>HER2-positive metastatic or locally recurrent unresectable breast cancer</td>
<td>Pertuzumab +trastuzumab+docetaxel</td>
<td>Placebo +trastuzumab + docetaxel</td>
<td>74</td>
<td>49.6</td>
<td>2013</td>
<td>51643</td>
<td>46608</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
### Table 1

<table>
<thead>
<tr>
<th>Medicine name</th>
<th>Active substance</th>
<th>Clinical setting</th>
<th>Treatment group</th>
<th>Control group</th>
<th>PFS TRT (median in weeks)</th>
<th>PFS CRT (median in weeks)</th>
<th>OS TRT (median in weeks)</th>
<th>OS CRT (median in weeks)</th>
<th>ORR TRT (%)</th>
<th>ORR CRT (%)</th>
<th>Year first authorization</th>
<th>Official negotiated price (£)</th>
<th>Discounted price (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kadcyla</td>
<td>Trastuzumab</td>
<td>HER2-positive, unresectable locally advanced or metastatic breast cancer</td>
<td>Trastuzumab emtansine (tdm1)</td>
<td>Lapatinib + capecitabine</td>
<td>38.4</td>
<td>25.6</td>
<td>123.9</td>
<td>100.4</td>
<td>56.1</td>
<td>22.6</td>
<td>2013</td>
<td>87215</td>
<td>75877</td>
</tr>
<tr>
<td>Giotrif</td>
<td>Afatinib</td>
<td>Locally advanced or metastatic NSCLC with activating EGFR mutation(s)</td>
<td>Afatinib</td>
<td>Pemetrexed (lyophilised powder)+cisplatin (solution for infusion)</td>
<td>44.56</td>
<td>27.6</td>
<td>56.1</td>
<td>22.6</td>
<td>56.1</td>
<td>22.6</td>
<td>2013</td>
<td>29528</td>
<td>21853</td>
</tr>
<tr>
<td>Stivarga</td>
<td>Regorafenib</td>
<td>Metastatic colorectal cancer (MCRC)</td>
<td>Regorafenib+best supportive care</td>
<td>Placebo+best supportive care</td>
<td>8.4</td>
<td>7.4</td>
<td>28</td>
<td>21.6</td>
<td>1</td>
<td>0.4</td>
<td>2013</td>
<td>85800</td>
<td>77434</td>
</tr>
<tr>
<td>Tafinlar</td>
<td>Dabrafenib</td>
<td>Unresectable or metastatic gastrointestinal stromal tumours</td>
<td>Dabrafenib</td>
<td>Dacarbazine</td>
<td>27.6</td>
<td>10.8</td>
<td>72.8</td>
<td>62.4</td>
<td>59</td>
<td>24</td>
<td>2013</td>
<td>107935</td>
<td>87670</td>
</tr>
<tr>
<td>Zaltrap</td>
<td>Afibercept</td>
<td>MCRC</td>
<td>Afibercept+folfox</td>
<td>Placebo+folfox</td>
<td>27.6</td>
<td>18.7</td>
<td>54</td>
<td>48.4</td>
<td>19.8</td>
<td>11.1</td>
<td>2013</td>
<td>30576</td>
<td>27591</td>
</tr>
<tr>
<td>Xtandi</td>
<td>Enzalutamide</td>
<td>Metastatic castration resistant prostate cancer</td>
<td>Enzalutamide</td>
<td>Placebo</td>
<td>33.2</td>
<td>11.6.6</td>
<td>73.6</td>
<td>54.4</td>
<td>2013</td>
<td>49184</td>
<td>31960</td>
<td>2013</td>
<td>127985</td>
</tr>
<tr>
<td>Imnovid</td>
<td>Pomalidomide</td>
<td>Relapsed and refractory multiple myeloma</td>
<td>Pomalidomide+Ld-dexamethasone</td>
<td>Hd dexamethasone</td>
<td>15.7</td>
<td>8</td>
<td>34</td>
<td>2013</td>
<td>127985</td>
<td>101646</td>
<td>2013</td>
<td>127985</td>
<td>101646</td>
</tr>
<tr>
<td>Lynparza*</td>
<td>Olaparib</td>
<td>Platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer</td>
<td>Olaparib</td>
<td>Placebo</td>
<td>33.6</td>
<td>19.2</td>
<td>119.2</td>
<td>111.2</td>
<td>2014</td>
<td>70517</td>
<td>52142</td>
<td>2014</td>
<td>62398</td>
</tr>
<tr>
<td>Cyramza</td>
<td>Ramucirumab</td>
<td>Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression</td>
<td>Ramucirumab+paclitaxel</td>
<td>Placebo+paclitaxel</td>
<td>17.6</td>
<td>11.6</td>
<td>38.4</td>
<td>29.6</td>
<td>27.9</td>
<td>16.1</td>
<td>2014</td>
<td>87360</td>
<td>78842</td>
</tr>
<tr>
<td>Mekinist</td>
<td>Trametinib</td>
<td>Unresectable or metastatic melanoma with a BRAF V600 mutation</td>
<td>Trametinib</td>
<td>Chemotherapy (dacarbazine or paclitaxel)</td>
<td>19.6</td>
<td>6</td>
<td>62.4</td>
<td>45.2</td>
<td>19</td>
<td>5</td>
<td>2014</td>
<td>62398</td>
<td>28157</td>
</tr>
<tr>
<td>Imbruvica</td>
<td>Ibrutinib</td>
<td>Chronic lymphocytic leukaemia (CLL)</td>
<td>Ibrutinib</td>
<td>Chlorambucil</td>
<td>75.6</td>
<td>56.8</td>
<td>53.6</td>
<td>29.4</td>
<td>82.4</td>
<td>35.3</td>
<td>2014</td>
<td>73805</td>
<td>51663</td>
</tr>
<tr>
<td>Zydelig</td>
<td>Idenalisib</td>
<td>CLL</td>
<td>Idenalisib+rituximab</td>
<td>Placebo+rituximab</td>
<td>22</td>
<td>74.5</td>
<td>14.5</td>
<td>2014</td>
<td>48667</td>
<td>34067</td>
<td>2014</td>
<td>66104</td>
<td>29829</td>
</tr>
<tr>
<td>Sylvant</td>
<td>Siltuximab</td>
<td>Multicentric Castleman disease</td>
<td>Siltuximab+best supportive care</td>
<td>Placebo+best supportive care</td>
<td>37.7</td>
<td>3.8</td>
<td>2014</td>
<td>27.9</td>
<td>16.1</td>
<td>2014</td>
<td>66104</td>
<td>29829</td>
<td>2014</td>
</tr>
<tr>
<td>Keytruda</td>
<td>Pembrolizumab</td>
<td>Advanced (unresectable or metastatic) melanoma</td>
<td>Pembrolizumab</td>
<td>Ipilimumab</td>
<td>22</td>
<td>11.2</td>
<td>33.7</td>
<td>11.9</td>
<td>2015</td>
<td>90400</td>
<td>81586</td>
<td>2015</td>
<td>90400</td>
</tr>
</tbody>
</table>

*Continued*
<table>
<thead>
<tr>
<th>Medicine name</th>
<th>Active substance</th>
<th>Clinical setting</th>
<th>Treatment group</th>
<th>Control group</th>
<th>PFS TRT (median in weeks)</th>
<th>PFS CRT (median in weeks)</th>
<th>OS TRT (median in weeks)</th>
<th>OS CRT (median in weeks)</th>
<th>ORR TRT (%)</th>
<th>ORR CRT (%)</th>
<th>Year first authorization</th>
<th>Official negotiated price ($)</th>
<th>Discounted price ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opdivo</td>
<td>Nivolumab</td>
<td>Advanced (unresectable or metastatic) melanoma</td>
<td>Nivolumab 3 mg/kg</td>
<td>Investigator choice I</td>
<td>18.8</td>
<td>16.8</td>
<td>31.7</td>
<td>10.6</td>
<td>2015</td>
<td>81310</td>
<td>71181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opdivo</td>
<td>Nivolumab</td>
<td>Locally advanced or metastatic NSCLC</td>
<td>Nivolumab 3 mg/kg</td>
<td>Docetaxel 75 mg/m²</td>
<td>9.32</td>
<td>16.8</td>
<td>48.8</td>
<td>37.4</td>
<td>2015</td>
<td>81310</td>
<td>71181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opdivo</td>
<td>Nivolumab</td>
<td>Advanced RCC</td>
<td>Nivolumab 3 mg/kg</td>
<td>Everolimus 100 mg</td>
<td>18.4</td>
<td>17.8</td>
<td>100</td>
<td>78.2</td>
<td>25.1</td>
<td>5.4</td>
<td>81310</td>
<td>in negotiation</td>
<td></td>
</tr>
<tr>
<td>Lenvima</td>
<td>Lenvatinib mesylate</td>
<td>Progressive, locally advanced or metastatic, differentiated (papillary/ follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine</td>
<td>Lenvatinib</td>
<td>Placebo</td>
<td>73.2</td>
<td>14.4</td>
<td>64.8</td>
<td>1.5</td>
<td>2015</td>
<td>68433</td>
<td>58673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cotellic</td>
<td>Cobimetinib hemifumarate</td>
<td>Unresectable or metastatic melanoma with a BRAF V600 mutation</td>
<td>Cobimetinib + vemurafenib</td>
<td>Placebo + vemurafenib</td>
<td>45.2</td>
<td>24</td>
<td>67.6</td>
<td>44.8</td>
<td>2015</td>
<td>75374</td>
<td>54420</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kyprolis</td>
<td>Carfilzomib</td>
<td>Multiple myeloma who have received at least one prior therapy</td>
<td>Carfilzomib + lenalidomide + dexamethasone</td>
<td>Lenalidomide + dexamethasone</td>
<td>105.2</td>
<td>70.4</td>
<td>87.1</td>
<td>67.7</td>
<td>2015</td>
<td>75900</td>
<td>44525</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*During the evaluation at the EMA, lyparza was found to be more effective in a subgroup of patients with a specific biomarker with the following outcome results: PFS lyparza: 44.8 w; PFS control: 17.2 w; OS lyparza: 139.6 w; OS control: 127.6. CRT, Control Patients; EGFR, Epidermal Growth Factor Receptor; EMA, European Medicines Agency; ORR, objective response rate; OS, overall survival; PFS, progression free survival; TRT, Patients with treatment.
available for 17, 29 and 29 indications, respectively. Each drug–indication pair contributed to one or more of these analyses, depending on which outcomes were reported in the EPAR.

In the treatment groups, the median improvements in the OS and PFS were 11.4 weeks (IQR 8.8–17.2; min 13.2; max 23.5) and 12.8 weeks (IQR 6.4–17; min –7.48; max 58.8), respectively; median ORR improvement in the treatment group was 21.8% (IQR 10–34.6; min –3; max 63.3). The reported ranges have negative minimum values since in two cases—nivolumab for NSCLC and regorafenib for gastrointestinal stromal tumours—the experimental treatment had a negative effect on one of the outcomes compared with the control group (in terms of PFS for nivolumab and ORR for regorafenib). The median negotiated price for a 1-year treatment was €72,392 (IQR 53,819–85,800; min 4,942; max 142,785), which was further discounted by 25% (on average) after applying confidential rebates. For all anticancer drugs but ipilimumab the price was calculated as 1-year treatment since the posology reported in the SPC reported that the treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. In the case of ipilimumab, the price was calculated as a course of four doses as reported in the SPC.

The official (ex-factory) price of new anticancer drugs and absolute clinical outcomes showed no correlation (figure 1A–C). The relationship between the improvement in median OS (in weeks) and negotiated price was estimated for 16 drugs (17 indications), and no correlation was observed ($R^2=0.067$). When clinical outcomes were expressed as absolute advantage in median PFS or ORR, 25 drugs (29 indications) were available for analysis, and in these cases, no correlation was observed ($R^2=0.004$ and 0.006, respectively).

Repeating the analyses and taking into account the additional confidential rebates, which are compulsory for hospital procurement, no improvement in the benefit/price relationships was highlighted (figure 2A–C). These findings also remained unchanged when the analyses were repeated with adjustments for tumour type (online supplementary table 1) or when clinical outcome was expressed as a percentage of improvement instead of as an absolute difference (online supplementary figure 1A–C). Sensitivity analyses that excluded negative improvements in outcomes over a control group (online supplementary figure 2) and considered only data from placebo-controlled trials (online supplementary figure 3A) confirmed the main analysis. The exploratory subgroup analyses by tumour type did not identify specific positive correlation patterns depending on tumour setting (online supplementary figure 4A–C).

**DISCUSSION**

This study is the first attempt to evaluate whether there were better correlations between cancer drug prices and clinical outcomes in a setting where central price negotiations are mandatory for every new medicine. Our study gave unexpected results to the research question, highlighting no relationships between cost of cancer drugs and benefits. Moreover, all prespecified sensitivity and subgroup analyses confirmed the main findings. This finding will have important policy implications both for countries like USA where price negotiations are absent and for other countries like Italy where price negotiations do exist.

In our study, the correlation between drug costs and clinical outcomes was even lower than the ones previously noted in the US context showing that negotiations did not tilt the relationship between drug prices and benefit positively. Thus, higher drug pricing remains despite the Italian legislative environment, where approval based on cost-effectiveness analysis and price negotiations have been mandatory by law since 2001. This finding may cast doubts on the role of the negotiation itself. However, it is important to understand that countries like Italy that negotiate drug prices do such negotiations only for binary decisions of approval or no-approval, not taking into account the additional confidential rebates, which are compulsory for hospital procurement.
account, during negotiation, a clear correlation between prices and benefits. This understanding is important for cancer policy decisions.

Indeed, there is no legal policy in any country to negotiate prices differently for drugs approved on the basis of surrogate endpoints versus survival outcomes, or drugs that improve survival in days, versus those that improve survival in months or drugs with immature benefit risk profiles. Although steps in the right direction, in lack of such policy, the value frameworks proposed by organisations such as ASCO, ESMO or NCCN have become little more than intellectual exercises.

Another reason price negotiations did not achieve better price–value correlations is that because of the global market of drugs, each single country—although large—only represents a small portion of the consumer market. Thus, companies ‘wield the stick’, setting the maximum price that the market will bear. In addition, in Italy, no threshold for incremental cost-effectiveness ratio (ICER) has been determined; thus, no limit is in place to be used as a decision rule in resource allocation at the time of negotiation/reimbursement decisions. The lack of such kind of cut-off might have contributed to the negative results in our study. However, we recognise that even when a threshold for ICER is well established, such as in the UK, continuous exceptions have been allowed in the case of anticancer drugs. For example, an ad hoc fund established in 2010 (ie, the Cancer Drug Fund) was recently dismissed by the Parliament because it did not deliver meaningful value to patients or society.

In the EU context (where newer anticancer drugs are approved by EMA without considering the added-value or cost-effectiveness), the complexity further increases because once a marketing authorisation is granted, it may become difficult to manage the reimbursement issue at a national level. Moreover, it is also difficult for payers (NHS/insurance) to defend the thesis against the public opinion that an anticancer drug cannot be reimbursed because it is too expensive. Indeed, as our study shows, the confidential discounts following negotiations between a member state and a company do not ameliorate the correlation between treatment costs and benefits even though they reduce absolute drug prices.

Another factor that negatively influences the contractual power of negotiation is non-transparent information on drug prices across countries. Difficulties in retrieving full information on prices have been already recognised in a recent survey comparing prices of anticancer drugs in 16 EU countries, Australia and New Zealand. Vogler et al found that price information is scarce and not disclosed due to confidential discounts or managed entry agreements (MEAs), calling for higher transparency. The authors state that it is in the interest of policy-makers to remove clauses limiting disclosure on price information because they risk overpaying when setting prices through external price referencing. This concern might be relevant in the Italian context since the negotiation procedure for reimbursement takes into account the price in other EU countries as well as the price of similar products within the same pharmacotherapeutic group.

We believe that two partly independent approaches could be adopted by policy-makers to achieve a better balance between cancer drug prices and benefits. First, price negotiations should be more strictly based on the level of evidence as well as the magnitudes of benefit. An ICER measure (such as QALY) should represent a threshold for reimbursement, thus setting a starting point for price negotiation and adjusting the ICER threshold based on the magnitude of the relative benefit reached. If the information on the relative value is not available at the time of negotiation, comparisons can be performed using indirect techniques, whereas after entering the market, payers should play a major role in supporting the evidence-generating process.

The second approach that could attain lower prices would require an increased transparency on the costs of drug development process, including the relative contributions from academia and public sector to the development of a drug. For instance, research conducted...
to evaluate efforts of drug development processes highlighted that about half of the most transformative drugs approved by the FDA had substantial contributions to their development by academic researchers supported by government funding. In addition, it has been estimated that the cost of late clinical development takes a limited part of the whole process. It is probably the right time to appropriately acknowledge the contributions of publicly funded research during drug price negotiation with companies. Often, comparative effectiveness research is funded by public institutions to test different treatments in real practice on robust outcomes with longer follow-up or special populations. The findings of these studies should be linked to a continuous price renegotiation over the life cycle of a product.

Other approaches identified as possible solutions to keep the health system sustainable address the general governance of the system, that is, when the price is already set. In fact, a price-volume approach or indication-based pricing have been modelled, each presenting pros and cons. Moreover, given that different oncology settings appear to be oligopolistic, thus refraining from price competition, another possible solution comes from national/regional tenders among therapeutic categories when more alternatives are available.

The main limitations of our study concern data completeness on clinical outcome and price. We used, as an estimate of benefit, data from pivotal trials retrieved from EPARs. Moreover, we are not aware if further (more robust) data became available at a later stage when the price was negotiated at the national level. Thus, we cannot exclude that the correlation between drug prices and therapeutic benefit might improve taking into account data acquired after the marketing of anticancer drugs.

Another important limitation is that we have not considered quality of life outcomes as another metric of clinical benefit. Furthermore, a recent study has shown that quality of life outcomes are not routinely collected or published, and that the tools used to measure quality of life are varied to have a uniform metric for comparison. Although we have included surrogate measures such as PFS or ORR as clinical outcomes in our analysis because they were considered as the basis for approval by the regulatory agency, these surrogate measures do not always correlate with true clinical benefits in terms of improved survival or improved quality of life.

Regarding the price estimate, we estimated the treatment costs for 1-year treatment or for the total course in the case of ipilimumab where the treatment course lasts less than 1 year. However, the exclusion of ipilimumab would not alter the main findings.

Another factor that might have impacted the price estimation is the rebate obtained at the regional/local level following drug tenders. This information was not available for the analyses and would have been not generalisable at the national level. Moreover, additional savings were expected ‘a posteriori’ from the MEAs in place in Italy (whose information is not publicly available) and were not considered in the analyses.

Our study is a retrospective cross-sectional correlation study that aimed at evaluating whether central price negotiation (mandatory by law in Italy) leads to better alignment of prices and the benefits known at the time of drug approval. This means that our analysis is not aimed at comparing costs and outcomes within drug classes, as a typical cost-effective study, and we never intended to assess the added values of the approved drugs in the context of all other drugs sharing the same indication. The ‘population’/cohort approach that we adopted has the intrinsic limitation of including drugs approved for different indications or different cancer types (with various incidence/prevalence) based on different clinical data packages. The consequent heterogeneity stemming from this approach was resolved adjusting the correlation analyses by tumour type or conducting several subanalyses. Following this approach, we found results consistent with primary findings thus confirming the robustness of methods and results.

**CONCLUSION**

Our results suggest that price negotiations for approval decisions alone may not bring balance between prices and benefits of anticancer drugs. Based on the limited outcome data available at the time of reimbursement decisions (OS, PFS and ORR), prices of anticancer drugs do not reflect their therapeutic benefit. Other strategies, such as value-based price negotiations, price negotiations strictly based on strength of evidence and price transparency, may be necessary to better achieve the drug prices and benefits balance. These results need to be confirmed in other countries where a national price negotiation exists.

**Contributors** FT, NM and AA conceptualised the study, FT, AA, NM, FM, FB-A, GT and RDC designed the study. FB-A, RP, IE and NM were in charge of data extraction and quality control. FM, RDC and FT performed the data analysis. FT, RDC, FM, GT, BG, FP and AA drafted the manuscript; all the authors contributed to the discussion and the interpretation of results and reviewed the final version of the manuscript. All authors approved the final manuscript as submitted.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** FP has received personal fees unrelated to the work presented in this article from Bayer, Ipsen, Astra Zeneca, Bristol Myers Squibb, Sandoz, Incyte, Celgene, Pierre Fabre, Janssen-Cilag.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as online supplementary information.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**ORCID iD**

Antonio Addesa [http://orcid.org/0000-0003-0962-9959](http://orcid.org/0000-0003-0962-9959)
REFERENCES


2 Ghisletta N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? challenging the high price of new drugs. BMJ 2016;352.


7 Szabo L. Cancer patients skipping medications or delaying treatment due to high drug prices. STAT 2017;15.


26 Sobrero A, Bruzzi P. Incremental advance or seismic shift? the need to raise the bar of efficacy for drug approval. JCO 2009;27:968–73.


35 Kesselheim AS, Tan YT, Avorn J. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff 2015;34:286–93.


